The agreement aims at advancing the clinical efficiency of Bronchial Thermoplasty, a new outpatient procedure that delivers precisely controlled thermal energy to minimize excess airway smooth muscle related with airway constriction in patients suffering with asthma.

By minimizing the capability of the airways to constrict, the new treatment helps patients with severe asthma to gain better control over the disease.

Mayo Clinic pulmonary and critical care medicine associate professor Craig Daniels said, "The development of a single treatment system that can be performed with precision and that can offer real time feedback of treatment efficacy in a single office visit, versus the three treatments that are currently required benefits patients and providers because it will reduce risk and save time and money."

According to the World Health Organization (WHO), asthama has caused 250,000 annual deaths and it is anticipated that by 2025, the number of people with asthma will increase as much as 25%, to more than 400 million people.

Mayo Clinic will take part in the development of the technology, which will be included into Sanovas’ portfolio of patents and therapy enabling technologies for pulmonary disease.

Sanovas will get exclusive worldwide license of the Mayo patent. Also, the products which are developed through this collaboration will be marketed exclusively by Sanovas.

Sanovas co-founder and CEO Larry Gerrans said, "The spirit of this collaboration is to combine Sanovas’ and Mayo Clinic’s respective technologies and expertise to advance precision in the treatment and control of asthma."

Mayo patent co- inventor and Mayo Clinic cardiovascular medicine and pediatrics professor Samuel Asirvatham said, "We are delighted to collaborate with Sanovas to advance the clinical science and capabilities in bronchial smooth muscle modification on behalf of these patients suffering from severe Asthma."